StockData

Generate Biomedicines, Inc. (GENB) company profile

GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)

Close on Nov 17, 2026Market cap $1.26BP/E –Yield –

About Generate Biomedicines

Pharmaceutical Preparations, SIC 2834

Generate Biomedicines, Inc. is listed on Nasdaq under the ticker GENB, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
Generate Biomedicines, Inc.
Headquarters
Somerville, MA
Address
101 South Street, Suite 900 02143
Phone
(888) 469-0055
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
GENB
Exchange
Nasdaq
IPO date
Feb 27, 2026
Shares outstanding
128M, Jul 29, 2026
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
2100782
CUSIP
370920100
ISIN
US3709201004
FIGI
BBG00X9D0NZ0
Share class FIGI
BBG00X9D0P03
EIN
83-1630228

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael NallyChief Executive Officer, Director2,889,154
Gevorg GrigoryanChief Technology Officer659,973
Beth GrousChief People Officer300
Laurie Anne LeeChief Medical Officer–
Jason SilversPresident & CFO1,500
Sean MartinChief Legal Officer & GC–
Aarif KhakooChief Scientific Officer–
Frances ArnoldDirector452,535
Paul Gray ParkerDirector–
Nancy A. SimonianDirector–
Jane L. MendilloDirector1,500
Marsha FanucciDirector–
Rupert VesseyDirector–
Noubar AfeyanDirector–
Stephane BancelDirector1,184,989

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 27, 2026
Offer price
$16.00
Securities offered
25,000,000
Gross proceeds
$400.00M
Exchange
Nasdaq
First trading day
Feb 27, 2026
First-day close
$12.65-20.9%
Lock-up ends (est.)
Aug 26, 2026

“The initial public offering price per share is $16.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?